Verdiva Bio
Last verified 2026-04-29. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $411.0Mattributed |
|---|---|
| Latest round | series-a, $411.0M, 2025-01-01attributed |
| Founded | 2024 |
| Headquarters | Guildford, UK |
| Industry | bio |
| Stage | series-a |
| Website | verdivabio.com |
Verdiva Bio is a UK biotech developing once-weekly oral GLP-1 analogs and other obesity and cardiometabolic therapies. Patients with obesity and cardiometabolic disease are the eventual customer base. Lead program VRB-101 is an oral ecnoglutide in Phase 2 clinical development.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | series-a | $411.0M | undisclosed |
Detected tech stack
Nginx, Mailcheck 1.1.2, Yoast SEO 27.6, reCAPTCHA, Google Analytics, Google Tag Manager, Slick, jQuery Migrate 3.4.1, jsDelivr, Plesk, punycode 1.0.0, DoubleClick Floodlight
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $411.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $411.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | verdivabio.com, read 2026-04-29 |
| Description | self-reported | verdivabio.com, read 2026-04-29 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.